Identifying proteomic risk factors for cancer using prospective and exome analyses: 1,463 circulating proteins and risk of 19 cancers in the UK Biobank

 $\begin{array}{c} 1 \\ 1 \\ 2 \end{array}$ Authors: Keren Papier**, Joshua R Atkins**, Tammy YN Tong*, Kezia Gaitskell *, Trishna Desai *, Chibuzor F Ogamba
¹, Mahboubeh Parsaeian ¹, Gillian K Reeves ¹, Ian G Mills^{2,3}, Tim J Key¹, Karl Smith-Byrne ¹⁺, R f, Mahboubeh Parsaeian f, Gillian K Reeves f, Ian G Millsfir, Tim J Keyf, Karl Smith-Byrneff, Ruth C Travisff
-, Mahboubeh Parsaeian⁻¹, Gillian K Reeves⁻¹, Ian G Mills^{2,3}, Tim J Key¹, Karl Smith-Byrne¹⁺, Ruth C Travis¹⁺
Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK

i
1

Cancer Epidemiology Unit, Number Epidemiology University, University, University, University, University
Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
Patrick G Johnston Centre for Cancer Resea "Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
³ Patrick G Johnston Centre for Cancer Research, Queen's University Belfast,
*Keren Papier and Joshua R Atkins are shared first authors. ⁺Karl ° Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK
*Keren Papier and Joshua R Atkins are shared first authors. ⁺Karl Smith-Byrne and Ruth (
equally.
Conflict of interests: None
Ru *Keren Papier and Joshua R Atkins are shared first authors. †
equally.
Conflict of interests: None
Running title: Plasma proteins and cancer risk
... Karl Smith-Byrne and Ruth C Travis contributed equally.
<mark>Conflict</mark>
Running
Keyword

**Conflict of interests: None
Running title: Plasma proteins and cancer risk**

Keywords: cancer; protein, proteomics, prospective, cohort, incidence, risk, exome, genetic risk score

Financial support:

This work was supported by Cancer Research UK (grant numbers C8221/A29017 and C8221/A29186) to fund the
centralized pooling, checking and data analysis. Tammy Tong is supported by an NDPH fellowship. Keren Papier is $\begin{array}{c} \n\blacksquare \quad \blacksquare \quad \$ This work was supported by the Cancer Research UK supported by an NDPH fellowship. Keren Papier is
supported by Wellcome, Our Planet Our Health (Livestock, Environment and People—LEAP) [grant number
205212/Z/16/Z]. Trishna cupported by Wellcome, Our Planet Our Health (Livestock, Environment and People—LEAP) [grant number
205212/Z/16/Z]. Trishna Desai is supported by a Cancer Research UK studentship (grant number C8221/A30904).
Chibuzor F. Og 205212/Z/16/Z]. Trishna Desai is supported by a Cancer Research UK studentship (grant number C8221/A30904).
Chibuzor F. Ogamba is supported by an NDPH studentship. The funders had no role in study design, data collection,
 205212. Thibuzor F. Ogamba is supported by an NDPH studentship. The funders had no role in study design, data collection,
Analysis, decision to publish, or preparation of the manuscript.
Correspondence to: Keren Papier, Ca

analysis, decision to publish, or preparation of the manuscript.
 Correspondence to: Keren Papier, Cancer Epidemiology Unit, Nuffield Department of Population Health, University

of Oxford, Richard Doll Building, Rooseve correspondence to: Keren Papier, Cancer Epidemiology Unit, N
Analysis, decision of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7 $\ddot{}$ Correspondence to: Keren Fapier, Cancer Epidemiology Unit, Numera Department of Population Health, University
of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, UK.
Email: keren.papier@ndph.ox.ac.uk

of Oxford, Richard Doll Building, Richard Drive, Oxford, 2012
Tel: +44 1865 289641
Email: keren.papier@ndph.ox.ac.uk Tel: +44 1865 289641
Email: keren.papier@ndph.ox.ac.uk

$\begin{array}{c} \n\end{array}$ Conflict of interest statement:

The authors disclose no potential conflicts of interest.

Abbreviations: CI, confidence interval; cis-pQTL, cis protein quantitative trait locus; exGS, exome-wide genetic
score; HR, hazard ratio; pLI, probable loss-of-function intolerant. Abbreviations: CI, confidence interval; *cis-pQTL*, *cis-protein quantitative trait locus*; exos, exome-wide generic
score; HR, hazard ratio; pLI, probable loss-of-function intolerant.

Background

Abstract (n=390)
Background
Proteins are esse
tumor onset. The
Biobank has enab
sites and their po Proteins are essential for the development and progression of cancer and for the human body's defense against
tumor onset. The availability of a large panel of protein measurements and whole exome sequence data in the UK
B Biobank has enabled the simultaneous examination of plasma protein associations with risk across multiple cancer
sites and their potential role in cancer etiology.
Methods
We investigated the associations of plasma protein

Methods

Sites and their potential role in cancer etiology.
 Methods

We investigated the associations of plasma proteins with incidence of 19 cancers and 9 cancer subsites in up to

44,645 middle-aged adults in the UK Biobank, w Methods
We investigated the associations of plasma pro
44,645 middle-aged adults in the UK Biobank,
Olink Explore Proximity Extension Assay in base
regression, we estimated the risk of each n 44,645 middle-aged adults in the UK Biobank, who had measurements of 1,463 plasma proteins generated using
Olink Explore Proximity Extension Assay in baseline blood samples (2006-2010). Using multivariable-adjusted Cox
reg 44,445 minimum approximity Extension Assay in baseline blood samples (2006-2010). Using multivariable-adjusted Cox
regression, we estimated the risk of each protein with each cancer overall and by time-to-diagnosis after
c The Exploration Assays in the risk of each protein with each cancer overall and by time-to-diagnosis after
correction for multiple-testing. Identified protein-cancer associations were further assessed in an analysis of
can correction for multiple-testing. Identified protein-cancer associations were further assessed in an analysis of
cancer risk using *cis*-pQTL and exome-wide protein genetic scores (exGS) in all UK Biobank participants
(n=33 cancer risk using cis-pQTL and exome-wide protein genetic scores (exGS) in all UK Biobank participants
(n=337,543).
Results
We identified 371 proteins associated with the risk of at least one incident cancer, represented b

Results

cancer risk using cis-pQTL and exome-wide protein genetic scores (exds) in all UK Biobank participants
(n=337,543).
We identified 371 proteins associated with the risk of at least one incident cancer, represented by a tota Results
We identified
protein-cance
kidney (51),
ovary (2), bla protein-cancer associations. These proteins were associated with cancers of the blood (201 proteins), liver (131),
kidney (51), lung (28), esophagus (22), colorectum (15), stomach (8), breast (5), prostate (3), endometrium bridney (51), lung (28), esophagus (22), colorectum (15), stomach (8), breast (5), prostate (3), endometrium (3), ovary (2), bladder (1), head and neck (1), and brain (1). 100 of these 621 protein-cancer associations persi ovary (2), bladder (1), head and neck (1), and brain (1). 100 of these 621 protein-cancer associations persisted for
cases diagnosed more than seven years after blood draw. Of these 621 associations, there was further supp From *City Martian (1), head and neck (1),* and and neck (1). The set of these 621 associations, there was further support from *cis-*pQTL analyses for the etiological role of TNFRSF14 in risk of non-Hodgkin lymphoma (NHL) From *cis*-pQTL analyses for the etiological role of TNFRSF14 in risk of non-Hodgkin lymphoma (NHL), and from whole exome protein score (exGS) analyses for 28 other protein-cancer associations, including SRP14 and risk of from cis-pQTL analyses for the etiological role of TNFRSF14 in Fisk of non-Hodgkin lymphoma (NHL), and from
whole exome protein score (exGS) analyses for 28 other protein-cancer associations, including SRP14 and risk of
le where entering protein score (enter) analyses for leading protein scheme and conditionally concerned by concordant evidence from long time-to-diagnosis analyses and from both *cis*-
pQTL and exGS analyses were SFTPA2 for l

pQTL and exGS analyses were SFTPA2 for lung cancer, TNFRSF1B and CD74 for NHL, and ADAM8 for leukemia.
 Conclusions

For the first time using an integrated multi-omics and cross-cancer approach, we have comprehensively a poor the first time using an integrated multi-omics and cross-cancer approach, we have comprehensively asset
the plasma proteome in relation to cancer risk and identified multiple novel etiological candidates. Difference
t For the first
the plasma p
the levels of
of these are
concordant e the plasma proteome in relation to cancer risk and identified multiple novel etiological candidates. Differences in
the levels of many circulating proteins were detectable more than seven years before cancer diagnosis; whi the levels of many circulating proteins were detectable more than seven years before cancer diagnosis; while some
of these are likely to be markers of early cancer processes that may inform risk stratification, and/or risk of these are likely to be markers of early cancer processes that may inform risk stratification, and/or risk factors, concordant evidence from genetic analyses suggests that some may have a role in cancer development. concordant evidence from genetic analyses suggests that some may have a role in cancer development.

Introduction
Proteins are integral to most biological processes including many that lead to carcinogenesis, such as tissue growth and proliferation. Previous prospective studies of individual or small panels of blood proteins have identified
etiological cancer proteins, such as insulin-like growth factor-l, which is a causal risk factor for breast, and prostate cancer proteins, such as insulin-like growth factor-l, which is a causal risk factor for breast, colorectal,
and prostate cancers, and microseminoprotein-beta, which is associated with lower prostate cancer ri and prostate cancers, and microseminoprotein-beta, which is associated with lower prostate cancer risk. $1-3$ Other
cancer biomarkers identified include protein markers for early detection, progression, recurrence and pro and prostate cancers, and microseminoprotein-beta, which is associated with lower prostate cancer risk. ¹ Other
cancer biomarkers identified include protein markers for early detection, progression, recurrence and progno for example CA-125, CEACAM5, CA19-9 and prostate-specific antigen. $4-7$ However, new multiplex proteomics
methods allow for the simultaneous measurement of thousands of proteins, many of which have not previously
been as

for example CA-125, CEACAM5, CA19-9 and prostate-specific antigen. ⁴ However, new multiplex proteomics
methods allow for the simultaneous measurement of thousands of proteins, many of which have not previously
been asses methods allow for the simultaneous measurement of thousands of proteins, many of which have not previously
been assessed for their associations with risk across multiple cancer sites.
Identifying etiological markers of ca Identifying etiological markers of cancer risk using prospective data alone
for confounding and other epidemiological biases. However, the abundance
be at least partially explained by inherited genetic variation; these gen For confounding and other epidemiological biases. However, the abundance of many proteins in the circulation can
be at least partially explained by inherited genetic variation; these genetic predictors of protein levels c For conformaling and other the linear term in the conformalist predictors of protein levels can be used
to generate complementary evidence, with orthogonal biases, on protein-cancer associations.^{8–10} Many of these
geneti to generate complementary evidence, with orthogonal biases, on protein-cancer associations.⁸⁻¹⁰ Many of these
genetic variants lie in a protein's cognate gene (known as *cis* protein-cancer associations.⁸⁻¹⁰ Many of t genetic variants lie in a protein's cognate gene (known as cis protein quantitative trait loci [cis-pQTL]) and likely
influence biological processes directly, such as by transcription or translation, and can be highly robu influence biological processes the intervals, $^{11-13}$ Such genetic analyses complement traditional prospective epidemiology,
and the combination of observational and genetic approaches can improve our ability to identify

predictors of protein concentrations.¹¹ \sim Such genetic analyses complement traditional prospective epidemiology, and the combination of observational and genetic approaches can improve our ability to identify proteins and the combination of observational and general approach.¹⁴
Iikely to have a causal role in cancer development and progression.¹⁴
Here, we use an integrated multi-omics approach combining prospective cohort and exometo identify proteins with a role in cancer etiology: we describe the association of 1,463 protein biomarkers quantified using the Olink platform with risk of 19 common cancers and 9 cancer subsites in 44,645 UK Biobank par quantified using the Olink platform with risk of 19 common cancers and 9 cancer subsites in 44,645 UK Biobank participants, overall and by time to diagnosis. We further assess the identified protein-cancer associations as etiological risk factors using exome cis-pQTL variant and exome-wide genetic score analyses (exGS).

Methods Observational data

Study population

This study is based on data from the UK Biobank participants, a prospective cohort of 503,317 adults aged between 39 and 73, recruited between 2006 and 2010 from across the UK. The study design and rationale have been
described elsewhere.^{15,16} Briefly, eligible participants were those registered with the National Health Service in
 described elsewhere.^{15, 16} Briefly, eligible participants were those registered with the National Health Service in
England, Scotland or Wales who lived within travelling distance of one of the 22 assessment centers in t England, Scotland or Wales who lived within travelling distance of one of the 22 assessment centers in these regions. In total, ~5% of invited participants joined the study by attending a baseline visit, where they complet England, S. The total, ~5% of invited participants joined the study by attending a baseline visit, where they completed a touchscreen questionnaire, had anthropometric data and biological samples taken by trained staff, an regions. In the study of individual and biological samples taken by trained staff, and gave
informed written consent to be followed up through national record linkage. The study was approved by the
National Information Gov to the mediatry witten consent to be followed up through national record linkage. The study was approved by the
National Information Governance Board for Health and Social Care and the National Health Service Northwest
Mul information consent to be followed up through national correlatings in the study first to be followed National

Information Governance Board for Health and Social Care and the National Health Service Northwest

Influence a

Exposure and outcome assessment

Multicenter Research Ethics Committee (06/MRE08/65).
Exposure and outcome assessment
Non-fasting blood samples were collected from all participants at recruitment and plasma was prepared and
stored at –80°C. Protein measur Exposure and outcome assessment
Non-fasting blood samples were collected from all pair
stored at -80°C. Protein measurements were generate
participants selected as part of the UK Biobank Pharma *L*
「 S F i stored at -80°C. Protein measurements were generated using the Olink Proximity Extension Assay in 54,306
participants selected as part of the UK Biobank Pharma Proteomics Project (UKB-PPP). Samples were selected for
inclus participants selected as part of the UK Biobank Pharma Proteomics Project (UKB-PPP). Samples were selected for
inclusion in the UKB-PPP based on a number of factors described in detail elsewhere.¹⁷ In brief, an initial 5 participants in the UKB-PPP based on a number of factors described in detail elsewhere.¹⁷ In brief, an initial 5,500 were pre-selected by UKB-PPP members. A further 44,502 representative participant samples were selected were pre-selected by UKB-PPP members. A further 44,502 representative participant samples were selected from
the UK Biobank, stratified by age, sex, and recruitment center. The remaining samples were chosen as part of a the UK Biobank, stratified by age, sex, and recruitment center. The remaining samples were chosen as part of a
second picking process based on a variety of criteria including membership of a COVID-19 case-control imaging
s the UK Biobana, stratified by age, sex, and recruitment center. The remaining samples in the remaining second
second picking process based on a variety of criteria including membership of a COVID-19 case-control imaging
st study. Plasma samples were transferred to the Olink Analyses Service, Uppsala, Sweden for measurements. study. Plasma samples were transferred to the Olink Analyses Service, Uppsala, Sweden for measurements.

Olink assay technology and analyses are described in detail elsewhere.¹⁸ In brief, the relative abundance of 1,463 proteins was quantified using antibodies distributed across four 384-plex panels: inflammation, oncology, provident abolic, and neurology. Blood samples were assayed in four 384-well plates consisting of four abundance
blocks for each of the four panels per 96 samples using the Olink Explore platform, which is based on proximi Extension assays (PEA) that are highly sensitive and reproducible with low cross-reactivity. Relative concentrations
of the 1,463 unique proteins were readout by next-generation sequencing. Measurements are expressed as
no extension assays (PEA) that are highly sensitive and reproducible with low cross-reactivity. Relative concentrations
of the 1,463 unique proteins were readout by next-generation sequencing. Measurements are expressed as
no of the 1,463 unique proteins were readout by next-generation sequencing. Measurements are expressed as
normalized protein expression (NPX) values that are log-base-2 transformed. Protein values below the limit of
detectio normalized protein expression (NPX) values that are log-base-2 transformed. Protein values below the limit of
detection (LOD) were replaced with the LOD divided by the square root of 2 and each protein was rescaled to have detection (LOD) were replaced with the LOD divided by the square root of 2 and each protein was rescaled to have
a mean of 0 and a standard deviation (SD) of 1.¹⁹ Protein values were subsequently inverse rank normal
tran

a mean of 0 and a standard deviation (SD) of 1^{19} Protein values were subsequently inverse rank normal
transformed.
Cancer registration and death data were obtained through record linkage to national registries (NHS Di November 30, 2021, in Scotland) or until participants died, withdrew consent for future linkage or were reported Cancer regist

England and V

Health Index)

November 30

to have le England and Wales using participants' NHS numbers, and NHS Central Register for Scotland using the Community
Health Index). Data were available until the censoring date (December 31, 2020, in England and Wales and
November England and Wales and November 30, 2021, in Scotland) or until participants died, withdrew consent for future linkage or were reported to have left the United Kingdom. Further information on data linkage is available from November 30, 2021, in Scotland) or until participants died, withdrew consent for future linkage or were reported
to have left the United Kingdom. Further information on data linkage is available from
https://biobank.ndph.o November 30, 2022, in the United Kingdom. Further information on data linkage is available from

https://biobank.ndph.ox.ac.uk/crystal/crystal/docs/CancerLinkage.pdf). For the observational analyses, the

endpoints were de https://biobank.ndph.ox.ac.uk/crystal/crystal/docs/CancerLinkage.pdf). For the observational analyses, the
endpoints were defined as the first incident cancer diagnosis, or cancer first recorded in death certificate if the mapoints were defined as the first incident cancer diagnosis, or cancer first recorded in death certificate if there
was no previous record of a cancer diagnosis [all coded using the 10th revision of the World Health Organ was no previous record of a cancer diagnosis [all coded using the 10th revision of the World Health Organization's
International Statistical Classification of Diseases (ICD-10)]: head and neck (C00–14, C32), esophagus (C15 stomach (C16), colorectum (C18–20), liver (C22), pancreas (C25), lung (C34), malignant melanoma (C43), breast in
women (C50), uterine (C54), ovary (C56), prostate (C61), kidney (C64–65), bladder (C67), brain (C71), thyroid women (C50), uterine (C54), ovary (C56), prostate (C61), kidney (C64–65), bladder (C67), brain (C71), thyroid (C73),
and the blood cancer subgroups non-Hodgkin lymphoma (NHL; C82–85), multiple myeloma (C90), and leukemia
(and the blood cancer subgroups non-Hodgkin lymphoma (NHL; C82–85), multiple myeloma (C90), and leukemia (C91–95). The following subclassifications of these cancer groupings were also considered: oral (C00–14) and lip and (C91–95). The following subclassifications of these cancer groupings were also considered: oral (C00–14) and lip
and oral cavity (C00–06) within head and neck cancers (C00–14, C32); adenocarcinoma of esophagus (C15,
morph (C91–14). The following subclassive of the following subclassive cancers (C00–14), C32); adenocarcinoma of esophagus (C15, morphology codes ICD-0-3 8140–8573) within esophageal cancer (C15); colon (C18) and rectum (includi and orchology codes ICD-0-3 8140–8573) within esophageal cancer (C15); colon (C18) and rectum (including
rectosigmoid junction, C19–20) within colorectal cancer (C18–20); adenocarcinoma of lung (C34, morphology
codes ICD-0 morphology codes ICD-O-3 8140, 8211, 8250–8260, 8310, 8323, 8480–8490 and 8550), squamous cell carcinoma (C34, morphology codes ICD-O-3 8140, 8211, 8250–8260, 8310, 8323, 8480–8490 and 8550), squamous cell carcinoma (C34, rectors ICD-O-3 8140, 8211, 8250–8260, 8310, 8323, 8480–8490 and 8550), squamous cell carcinoma (C34, morphology codes ICD-O-3 8070-8072), small cell carcinoma (C34, morphology codes ICD-O-3 8070-8072), small cell carcinom morphology codes ICD-O-3 8070-8072), small cell carcinoma (C34, morphology codes ICD-O-3 8041-8042) within
lung cancer (C34); and DLBCL (C83) within NHL (C82–85). The person-years of follow-up were calculated from the
date lung cancer (C34); and DLBCL (C83) within NHL (C82–85). The person-years of follow-up were calculated from the
date of recruitment until the date of first registration of malignant cancer, death due to cancer, death, loss

date of recruitment until the date of first registration of malignant cancer, death due to cancer, death, loss or end
of follow-up, or censoring date, whichever came first.
Exome-sequencing in the UK Biobank and exonic pQT date of follow-up, or censoring date, whichever came first.

Exome-sequencing in the UK Biobank and exonic pQTL discovery

Exome-sequencing data preparation and quality control procedures in the UK Biobank have been previo Exome-sequencing in the UK Biobank and exonic pQT
Exome-sequencing in the UK Biobank and exonic pQT
Exome-sequencing data preparation and quality co
described.²⁰ In brief, exome capture was done using th
paired-end Illum Exome-sequencing in the UK Biobank and exonic pQTL discovery
Exome-sequencing data preparation and quality control procedures in the UK Biobank have been previously described.²⁰ In brief, exome capture was done using the IDT xGen Exome Research Panel v1.0 that underwent 75bp
paired-end Illumina sequencing on the NovaSeq 6000 platform using the S2 and S4 flow cells. BWA-MEM was used be map reads to GRCh38 with variant calling performed by DeepVariant using a 100bp buffer at each site of the custom target regions. We extracted 27,335 exome variants associated with circulating protein concentrations on custom target regions. We extracted 27,335 exome variants associated with circulating protein concentrations on
the Olink Explore panel at $p < 5x10^{-8}$ reported by Dhindsa *et al.* for 50,829 UK Biobank participants.²¹ The Olink Explore panel at $p < 5x10^8$ reported by Dhindsa *et al.* for 50,829 UK Biobank participants.²¹ The exome variants reported by Dhindsa *et al.* underwent a different pipeline using AstraZeneca's Genomics Resea variants reported by Dhindsa *et al.* underwent a different pipeline using AstraZeneca's Genomics Research (CGR)
bioinformatics pipeline.²¹ Single Nucleotide variants (SNV) and small insertions and deletions (INDEL) wer bioinformatics pipeline.²¹ Single Nucleotide variants (SNV) and small insertions and deletions (INDEL) were additionally annotated to SnpEFF v4.3 against Ensembl Build 38.92.²²
Exclusion and inclusion criteria
Of the

Exclusion and inclusion criteria

bioinformatics pipeline.²¹ Single Nucleotide variants (SNV) and small insertions and deletions (INDEL) were additionally annotated to SnpEFF v4.3 against Ensembl Build 38.92.²²
Exclusion and inclusion criteria
Of the additionally annotated to SnpEFF v4.3 against Ensembl Build 38.92.²²
Exclusion and inclusion criteria
Of the 54,306 participants who were selected for proteomic profilin
that did not pass quality control. From the rema That did not pass quality control. From the remaining 52,705, we further excluded 2,996 participants due to cancer
diagnosis at or prior to baseline (except non-melanoma skin cancer C44), 242 who had missing information on that dia not perform to baseline (except non-melanoma skin cancer C44), 242 who had missing information on
height or weight, 2,113 who were currently using hormone replacement therapy or oral contraceptives, and 2,709
heig height or weight, 2,113 who were currently using hormone replacement therapy or oral contraceptives, and 2,709 height or weight, 2,113 who were currently using hormone replacement therapy or oral contraceptives, and 2,709

who reported having diabetes at baseline. Following these exclusions, the maximal analysis cohort included 44,645
participants (see Extended Figure 1 for participant flowchart).
Statistical analysis
Observational analyses

Statistical analysis

Observational analyses

95% confidence intervals (CI) for each cancer site separately using Cox proportional hazards regression models s
A
S
N (/ ⊂ / r 95% confidence intervals (CI) for each cancer site separately using Cox proportional hazards regression models
with age as the underlying time variable. Missing data in covariates were handled by assigning participants to with age as the underlying time variable. Missing data in covariates were handled by assigning participants to an
"unknown" category for each respective variable. The minimally adjusted models were stratified by age group "unknown" category for each respective variable. The minimally adjusted models were stratified by age group at
recruitment (<45, 45–49, 50–54, 55–59, 60–64, and ≥ 65 years) and sex where applicable and adjusted for
ge mecruitment (<45, 45–49, 50–54, 55–59, 60–64, and ≥65 years) and sex where applicable and adjusted for geographical region (London, North-West, North-East, Yorkshire and Humber, West Midlands, East Midlands, South-East, So recruit in the second of texts. North-West, North-East, Yorkshire and Humber, West Midlands, East Midlands, South-East, South-West, Wales, and Scotland), and Townsend deprivation index (fifths, unknown). Multivariable-
adj geographical region (London, Water, Wales, and Scotland), and Townsend deprivation index (fifths, unknown). Multivariable-
adjusted models were additionally adjusted for cancer-specific risk factors (see Extended Methods). any adjaces were chosen upon review of the literature and restricted to variables available in the UK Biobank. We
used an effective number of tests (ENT) correction for multiple testing, applied in a family-wise manner by used an effective number of tests (ENT) correction for multiple testing, applied in a family-wise manner by cancer
type. The ENT method accounts for multiple testing by applying a Bonferroni correction that determines the
 type. The ENT method accounts for multiple testing by applying a Bonferroni correction that determines the
number of independent tests as the number of principal components needed to explain 95% of the variance in
protein

protein abundance. In this case, this was 639 independent tests.¹⁹
We examined protein and cancer-risk associations by time to diagnosis (diagnosed in <3 years, 3-7 years, and >7
years of follow-up) to investigate potent type. The ENT method accounts for multiple testing a y applying a Bondon content and accounts included and protein abundance. In this case, this was 639 independent tests.¹⁹
We examined protein and cancer-risk associatio number of independent tests as independent tests.¹⁹
protein abundance. In this case, this was 639 independent tests.¹⁹
We examined protein and cancer-risk associations by time to diagnosis (diagnosed in <3 years, 3-7 y ヽゝ こ F S c years of follow-up) to investigate potential effects of reverse causality. We also conducted a sensitivity analysis by self-reported sex (women and men) to investigate potential sex differences for protein-cancer associat years of freported sex (women and men) to investigate potential sex differences for protein-cancer associations that
passed multiple testing correction. We tested the heterogeneity of risk coefficients between the subgroup is passed multiple testing correction. We tested the heterogeneity of risk coefficients between the subgroups in each
stratified analysis using inverse variance weighting, testing for statistical significance with a χ 2 partiant multiple multiple interaction. Where weighting testing for statistical significance with a χ 2 test with k-1 degrees of freedom, where k is the number of subgroups.
Integrating existing publicly available datas

strating existing publicly available datasets on gene expression
Integrating existing publicly available datasets on gene expression
To provide greater biological context for identified protein-cancer associations, we extr Integrating existing publicly available datasets on gene expression from the Human Protein Atlas to describe mindle produce for the identified protein markers in our main obsextracted for genes in 30 different human tissue | |
| 6
| 6 Integrating existing publicly available datasets on gene expression
To provide greater biological context for identified protein-cancer associations, we extracted single cell RNA To pression from the Human Protein Atlas to describe mRNA expression in cancer-free individuals for genes that
code for the identified protein markers in our main observational analyses.²³ Normalized expression levels we extracted for the identified protein markers in our main observational analyses.²³ Normalized expression levels were
extracted for genes in 30 different human tissues and 82 cell-types. Gene expression specificity at the code for the identified protein markers in our main observational analyses.²³ Normalized expression levels were
extracted for genes in 30 different human tissues and 82 cell-types. Gene expression specificity at the cell extracted was calculated as the ratio of each gene cell-type or tissue expression to the total expression of each
gene across all cell or tissue types. We subsequently grouped genes into majority expression (more than 50% the actions all cell or tissue types. We subsequently grouped genes into majority expression (more than 50% of
total expression in each cell or tissue type) and enriched expression (between 10% and 50% of total expression gene across all cell or tissue types. We subsequently grouped generative majority expression (more main series
total expression in each cell or tissue). For proteins with either mRNA enriched or majority expression in at l total expression in at least of each cell-type or tissue). For proteins with either mRNA enriched or majority expression in at least one cell or tissue type, we also mapped these to their likely candidate cell and tissue o

each cell-type or tissue type or tissue). For proteins with either many entitypers in the proteins with the cell-
tissue type, we also mapped these to their likely candidate cell and tissue of origin where possible.
Integr Integrating existing publicly available datasets on drug targets
We gathered information on the potential *druggability* of proteins with evidence of a cancer risk and
main analyses by extracting information on whether a p Integrating existing publicly available datasets on drug targets
We gathered information on the potential *druggability* of proteins with evidence of a cancer risk association in our We gathered information on the potential druggability of proteins with evidence of a cancer risk association in our
main analyses by extracting information on whether a protein was the target of a known drug from the Open
 Targets Platform.²⁴ Subsequently, we filtered information from Open Targets to identify drugs that were approved and on the market by additionally cross-referencing against the ChEMBL database and other drug databases i and only including DailyMed and the Electronic Medicines Compendium.^{25–27} Proteins identified as the target of an available drug were additionally annotated with information on whether the effect of the drug would act t drug were additionally annotated with information on whether the effect of the drug would act to reduce or
increase the proposed protein association with cancer risk. derive a discontinuity and the proposed protein association with cancer risk.

Cis-pQTL and exome-wide genetic score on cancer outcomes

Sis-pQTL and exome-wide genetic score on cancer outcomes

increase the propose
Cis-pQTL and exome-wide genetic score on cancer outcom
. $\ddot{}$ Cis-pQTL and exome-wide genetic score on cancer outcomes

We further investigated protein-cancer associations identified after correction for multiple testing in observational analyses using two genetic approaches: single *cis*-pQTL risk analyses, where *cis*-pQTL were available analyses using two genetic approaches: single cis-pQTL risk analyses, where cis-pQTL were available for the protein
of interest, and using an exome-wide genetic score approach. No exonic variants were identified by Dhinds of IREEB, ING1, NPM1, PQBP1, SEPTIN9, KRT14 and ARTN and so were not considered in these analyses. In all exome-wide analyses, variants were oriented to the protein-increasing allele and exGS were calculated by summing th exome-wide analyses, variants were oriented to the protein-increasing allele and exGS were calculated by
summing the number of independent (clumping $r^2 < 0.01$, 10,000KB) protein-increasing alleles, weighted by betas
rep summing the number of independent (clumping $r^2 < 0.01$, 10,000KB) protein-increasing alleles, weighted by betas
reported in Dhindsa *et al.*, and projected in up to 337,543 European UK Biobank participants with exome-
se reported in Dimitiasa et al., and projected in up to 337,343 European OK Biobank participants with exome
sequencing (Extended Table 2) using PLINK2.²⁸ We subsequently used logistic regression models to estimate the
assoc sequencing (Extended Table 2) using PLINK2.²⁰ We subsequently used logistic regression models to estimate the association of each genetically predicted protein with cancer risk, using both *cis*-pQTL and exGS models, for association of each genetically predicted protein with cancer risk, dang both cis-pQTL and exos models, for each
protein-cancer association identified in observational analyses. Models were adjusted for by age, sex, and t protein-cancer associations of ancestry. For sex-specific cancers (breast, prostate, ovary and uterine), sex was excluded from the model. *Trans-pQTL* single variant analyses were conducted to contextualize which genes may excluded from the model. *Trans-pQTL* single variant analyses were conducted to contextualize which genes may
drive protein associations with cancer risk from exGS analyses. Additionally, we annotated exGS and single varia excluded from the model. Trans-pQTL single variant analyses were conducted to contextualize which genes hay
drive protein associations with cancer risk from exGS analyses. Additionally, we annotated exGS and single variant analyses with probable loss-of-function intolerance scores (pLI) from Gnomad and used IntOGen to annotate driver
genes.^{29,30} In the exome analysis, conventional significance was defined as $p < 0.05$, while Bonferroni co analysis, conventional significance was defined as $p < 0.05$, while Bonferroni correction was
used as the threshold for multiple test correction across the number of *cis-pQTL* or exGS analyzed for *cis-pQTL* or
exome-wide used as the threshold for multiple test correction across the number of cis-pQTL or exGS analyzed for cis-pQTL or
exome-wide genetic scores, respectively.

Combined evidence from prospective and genetic analyses

To enhance our understanding of a protein's likelihood of having a role in cancer etiology, we combined evidence example and general control to prospective and
Combined evidence from prospective and
To enhance our understanding of a prote
from observational long time-to-diagnos $\frac{1}{\epsilon}$ To enhance our understanding of a protein sandlyses (> 7 years between blood drawn and diagnosis), *cis*-pQTL
analyses, and exGS analyses, and categorized protein-cancer associations by degree of directionally concordant
s From observational long time-to-diagnosis analyses ($>$ 7 years between blood drawn and diagnosis), els pQTL
analyses, and exGS analyses, and categorized protein-cancer associations by degree of directionally concordant
s support from each of these three analyses. Acknowledging that not all proteins may have *cis*-pQTL, we ranked
proteins as most likely to be etiological risk factors if all three types of analyses supported an association a support from each of these three analyses. Acknowledging that not all proceins may have the perit, we ranked
proteins as most likely to be etiological risk factors if all three types of analyses supported an association at conventional significance, followed by long time-to-diagnosis and cis-pQTL analyses, then long time-to-diagnosis and exGS, exGS and cis-pQTL, and finally any one of long time-to-diagnosis, cis-pQTL, or exGS analyses.

RESULTS

Observational analyses

and exGS, exGS and cis-pQTL, and miany any one or long time-to-diagnosis, cis-pQTL, or exGS analyses.
RESULTS
Our prospective analyses included a total of 4.921 incident malignant cancer cases with a mean follo The median age at any cancer diagnosis was 66.9 years (Interquartile range (IQR) 9.9) [youngest median diagnosis was for breast cancer in women (median 64.5, IQR 12.5) and oldest for squamous cell carcinoma of the lung in years (see any). The meanings at any cancer in galactic rangular products (interquartile range (iQn) 9.9) (youngest
median diagnosis was for breast cancer in women (median 64.5, IQR 12.5) and oldest for squamous cell carci

median diagnosis for all cancer in the state cancer (median 1919) (Severically and other the squamous for all cancer
subsites.
Baseline characteristics of the analysis sample overall, by sex and in those who developed a ma of the lung in women (meaning in gradient 12, in the lung in the lung in the meaning generally and satisfy subsites.
Baseline characteristics of the analysis sample overall, by sex and in those who developed a malignant ca **Expreseded**
Baseline
follow-up
were you
were you follow-up are shown in Table 1. Compared with the total analysis sample, participants who developed a cancer
were on average older and a higher proportion of them were former or current smokers, moderate to high alcohol
co were on average older and a higher proportion of them were former or current smokers, moderate to high alcohol
consumers, and had a family history of various cancers; among the women, they reported having fewer children,
w consumers, and had a family history of various cancers; among the women, they reported having fewer children,
were younger at menarche, and a higher proportion of them were postmenopausal, had used hormone
replacement ther

consumers, and had a family history of the state of the were postmenopausal, had used hormone replacement therapy, and had never used the oral contraceptive pill.
From the 1,463 proteins included in our analyses, we identi replacement therapy, and had never used the oral contraceptive pill.
From the 1,463 proteins included in our analyses, we identified an association for 371 proteins with risk of at least
one cancer after correction for mul From the 1,463 proteins included in our analyses, we identified an as
one cancer after correction for multiple testing, which amounted to
Extended Table 3). Almost half of these associations (304) were for
body expression) From the 1,463 proteins included included in our and the 1,483 protein-cancer associations (Figure 1 & Extended Table 3). Almost half of these associations (304) were for proteins enriched (greater than 10% of total body e one cancer after the correction for multiple testing, which and cancer proteins enriched (greater than 10% of total
body expression) for mRNA expression in either the tissue or candidate cell of origin for the cancer indic Extended Table 3). Almost half of these associations (304) were for proteins enriched (greater than 20% of total
body expression) for mRNA expression in either the tissue or candidate cell of origin for the cancer indicate body expression) for mRNA expression in either the tissue or candidate cell of origin for the candidate cell o
The candidate cell of original cell of our

either the tissue or candidate cell of origin. Many of these associations were for proteins that were associated with
risk of hematological cancers with high mRNA expression in either B-cells or T-cells. However, we also i risk of hematological cancers with high mRNA expression in either B-cells or T-cells. However, we also identified
proteins that both associated with risk for cancer and either had enriched or majority mRNA expression in th

risk of hematological cancers with high manned engineer and either had enriched or majority mRNA expression in the
liver, lung, colorectum, kidneys, brain, stomach, esophagus, and endometrium (Figure 2).
More than half of proteins that both associations that both associations (Figure 2).

More than half of our ENT-significant protein-cancer associations (320) were for hematological malignancies

Hodgkin overall (NHL) [124], diffuse large B-More than half of our ENT-significant protein-cancer associations (320) were for hematol
Hodgkin overall (NHL) [124], diffuse large B-cell non-Hodgkin (DLBCL) [50], leukemia [87]
(59]). These included the associations of T Hodge in the included the associations of TNFRSF13B and SLAMF7 with risk of multiple myeloma [HR (95%Cl): 2.09
(1.96-2.24) and 3.07 (2.73-3.46), respectively], PDCD1 and TNFRSF9 with risk of NHL [1.99 (1.87-2.11) and 1.98
 (1.96-2.24) and 3.07 (2.73-3.46), respectively], PDCD1 and TNFRSF9 with risk of NHL [1.99 (1.87-2.11) and 1.98 (1.85-2.11), respectively], and FCER2 and FCRL2 with risk of leukemia [2.12 (1.98-2.29) and 2.10 (1.95-2.26),

We also observed associations between 131 proteins and risk of liver cancer that included IGFBP7 and IGFBP3 (1.85-2.11), respectively], and FCER2 and FCRL2 with risk of leukemia [2.12 (1.98-2.29) and 2.10 (1.95-2.26), respectively].
The spectively and S. 2.16 (1.95-2.26), respectively and TO and The S. 2.12 (1.98-2.29) and 2.10 (1.85 2.11), respectively], and FCER2 and FCRL2 with risk of liver cancer that included IGFBP7 and IGFBP3
[1.65 (1.48-1.84) and 0.46 (0.39-0.54), respectively], and 51 proteins and risk of kidney cancer, such as HAVCR1 and We also obse
[1.65 (1.48-1.8
ESM1 [2.88 (2
and/or at lea
1.56)]. Althou [1.65 (1.48-1.84) and 0.46 (0.39-0.54), respectively], and 51 proteins and risk of kidney cancer, such as HAVCR1 and ESM1 [2.88 (2.55-3.24) and 1.84 (1.55-2.19)]. We identified 28 proteins associated with risk of lung canc ESM1 [2.88 (2.55-3.24) and 1.84 (1.55-2.19)]. We identified 28 proteins associated with risk of lung cancer overall
and/or at least one histological subtype that included WFDC2 and CEACAM5 [1.52 (1.39-1.67) and 1.44 (1.33-ESM1 [2003] The state one histological subtype that included WFDC2 and CEACAM5 [1.52 (1.39-1.67) and 1.44 (1.33-1.56)]. Although most protein-cancer associations did not differ greatly between minimally and fully adjusted 1.56)]. Although most protein-cancer associations did not differ greatly between minimally and fully adjusted
models, some proteins associated with risk of lung cancer after ENT correction were attenuated by more than 50%
 models, some proteins associated with risk of lung cancer after ENT correction were attenuated by more than 50%
compared with minimally adjusted models, which may imply a potential risk for residual confounding stemming
fr

compared with minimally adjusted models, which may imply a potential risk for residual confounding stemming
from measurement error in smoking behaviors (Extended Figure 2).
Twenty-two proteins were associated with risk of from measurement error in smoking behaviors (Extended Figure 2).
Twenty-two proteins were associated with risk of esophageal cancer and/or esophageal adenocarcinoma,
including REG4 and ST6GAL1 [2.02 (1.66-2.45) and 1.83 (Twenty-two proteins were associated with risk of esophageal
including REG4 and ST6GAL1 [2.02 (1.66-2.45) and 1.83 (1.53-2.19
colorectal, colon, and/or rectal cancer, such as AREG and GDF15
proteins were associated with ris The proteins associated with risk of stomach cancer, such as STC2 and CRLF1 [1.33 (1.23-1.44) and 1.31 (1.22-1.41)]. Three proteins were associated with risk of stomach cancer including ANXA10 and TFF1 [1.76 (1.53-2.03) a colorectal, colon, and/or rectal cancer, such as AREG and GDF15 [1.30 (1.19-1.42) and 1.32 (1.20-1.45)]. Eight
proteins were associated with risk of stomach cancer including ANXA10 and TFF1 [1.76 (1.53-2.03) and 1.95 (1.63 proteins were associated with risk of stomach cancer including ANXA10 and TFF1 [1.76 (1.53-2.03) and 1.95 (1.63-
2.33)]. We found five proteins associated with risk of breast cancer, such as STC2 and CRLF1 [1.33 (1.23-1.44 proteins were associated with risk of stomach cancer including ANXA10 and TFF1 [1.76 (1.53-2.03) and 1.95 (1.63-2.33)]. We found five proteins associated with risk of breast cancer, such as STC2 and CRLF1 [1.33 (1.23-1.44) 2.23). Interpretation were associated with risk of prostate cancer: GP2, TSPAN1, and FLT3LG [1.29 (1.21-1.36), 1.14 (1.09-1.18), and 0.87 (0.82-0.92)] and three were associated with endometrial cancer: CHRDL2, KLK4, and W 1.21-1.36), 1.14 (1.09-1.18), and 0.87 (0.82-0.92)] and three were associated with endometrial cancer: CHRDL2,
KLK4, and WFIKKN1 [1.42 (1.21-1.65), 1.41 (1.20-1.65), and 1.42 (1.20-1.68)]. Two proteins were associated with KLK4, and WFIKKN1 [1.42 (1.21-1.65), 1.41 (1.20-1.65), and 1.42 (1.20-1.68)]. Two proteins were associated with risk of ovarian cancer, DKK4 and WFDC2 [1.46 (1.28-1.70), 1.57 (1.26-1.96)]. We identified one protein for eac Trisk of ovarian cancer, DKK4 and WFDC2 [1.46 (1.28-1.70), 1.57 (1.26-1.96)]. We identified one protein for each of bladder [WAS, 0.54 (0.39-0.73)], brain [GFAP, 1.55 (1.31-1.86)], and head and neck cancers [TPP1, 1.33 (1. risk of ovariant of our cancer associations was observed in these data for cancers [TPP1, 1.33 (1.16-1.52)]. Little evidence for protein associations was observed in these data for cancers of the pancreas, thyroid, lip and 1.52)]. Little evidence for protein associations was observed in these data for cancers of the pancreas, thyroid, lip and oral cavity, or melanoma after correcting for multiple testing. Limited heterogeneity was observed a stratifying the protein-cancer associations by sex, however none survived multiple testing correction (Extended stratifying the protein-cancer associations by sex, however none survived multiple testing correction (Extended
Table 4).
In stratified analyses, we identified 100 of the 621 ENT significant protein-cancer associations as

Analysis stratified by time between blood draw and diagnosis

stratifying the protein-cancer associations by sex, however none survived multiple testing correction (Extended
Table 4).
In stratified analyses, we identified 100 of the 621 ENT significant protein-cancer associations as Table 4).
Analysis
In stratifi
the anal
[hemato In stratificant analysis of cases diagnosed more than seven years after blood draw, representing 67 unique proteins
[hematological cancers: 37, liver: 12, lung: 9, stomach: 4, breast: 3, esophagus: 2, kidney: 2, colorectum The analysis of cases: 37, liver: 12, lung: 9, stomach: 4, breast: 3, esophagus: 2, kidney: 2, colorectum: 1] (Figure
3). Among the proteins associated with risk of hematological cancers, we identified associations with ri [hematological cancers: 77, 1991] Among the proteins associated with risk of hematological cancers, we identified associations with risk of multiple blood cancers for members of the fc-receptor protein [FCRL1, FCRL2, FCRL3 3). Among the proteins are the proteins of the fc-receptor protein [FCRL1, FCRL2, FCRL3, FCRL5, FCRLB] and TNF
receptor families [TNFRSF4, TNFRSF9, TNFRSF13B, TNFRSF13C, TNFSF13B, TNFSF13]. Among the 621 ENT
significant pr multiple framilies [TNFRSF4, TNFRSF9, TNFRSF13B, TNFRSF13C, TNFSF13B, TNFSF13]. Among the 621 ENT
significant protein-cancer associations, 290 were also ENT significant in the analysis of cases diagnosed within
three years reption that the protein-cancer associations, 290 were also ENT significant in the analysis of cases diagnosed within
three years of blood draw, representing 182 unique proteins [hematological cancers: 142, liver: 14, lung three years of blood draw, representing 182 unique proteins [hematological cancers: 142, liver: 14, lung: 12, colorectum: 10, kidney: 5, prostate: 2, stomach: 2, bladder: 1, esophagus: 1, breast: 1, brain: 1, ovary: 1], wh colorectum: 10, kidney: 5, prostate: 2, stomach: 2, bladder: 1, esophagus: 1, breast: 1, brain: 1, ovary: 1], which
may indicate effects of reverse causation.
Integrating existing publicly available datasets on drug target colorectum: 10, herectum: 1, prostate: 1, and the year of year (1, breast: 1, breast: 1, brain: 1, oral), 11, which
may indicate effects of reverse causation.
Integrating existing publicly available datasets on drug target

may indicate effects of reverse causation.
Integrating existing publicly available dat Integrating existing publicly available datasets on drug targets

We identified 38 proteins associated with the risk of at least one cancer that were also the target of a drug currently approved and available [hematological malignancies (20), liver (17), kidney cancer (7), esophageal
adenocarcinoma (1), and lung cancer (1)]. Most of these proteins were the target of monoclonal antibodies (21)
an currently approved and lung cancer (1)]. Most of these proteins were the target of monoclonal antibodies (21) and small molecule inhibitors (13). The proposed action for most of these drugs would be to reduce the cancer ri and small molecule inhibitors (13). The proposed action for most of these drugs would be to reduce the cancer risk
as indicated in our observational analyses, i.e. the drug would inhibit a protein positively associated wit as indicated in our observational analyses, i.e. the drug would inhibit a protein positively associated with cancer
risk. Nine of these proteins are also the target of drugs currently indicated for the treatment of the can risk. Nine of these proteins are also the target of drugs currently indicated for the treatment of the cancers
identified in our risk analyses. These include Dasatinib (EPHA2), Moxetumomab pasudotox (CD22) and Inotuzumab
o identified in our risk analyses. These include Dasatinib (EPHA2), Moxetumomab pasudotox (CD22) and Inotuzumab
ozogamicin (CD22) indicated in the treatment of leukemia subtypes, Brentuximab vedotin (TNFRSF8), Polatuzumab
ve ozogamicin (CD22) indicated in the treatment of leukemia subtypes, Brentuximab vedotin (TNFRSF8), Polatuzumab
vedotin (CD79B) and Pembrolizumab (PDCD1) indicated in the treatment of NHL subtypes including DLBCL,
Elotuzumab ordin (CD79B) and Pembrolizumab (PDCD1) indicated in the treatment of NHL subtypes including DLBCL,
Elotuzumab (SLAMF7) indicated in the treatment of multiple myeloma, and Regorafenib (EPHA2, PDGFRA, FGFR2)
indicated in th Elotuzumab (SLAMF7) indicated in the treatment of multiple myeloma, and Regorafenib (EPHA2, PDGFRA, FGFR2) indicated in the treatment of liver cancers (Extended Table 5).
Circulating proteins with both prospective and sing

Circulating proteins with both prospective and single cis-variant associations

Elotuzuma (SLAMF7) indicated in the treatment of liver cancers (Extended Table 5).

Circulating proteins with both prospective and single *cis*-variant associations

Using 939 *cis*-pQTL, which represented 294 unique prot Circulating proteins with both prospective and single *cis*-varia
Using 939 *cis*-pQTL, which represented 294 unique protein
associations that were identified after multiple testing in th
TNFRSF14 were associated with a lo basing 939 cis-pQTL, which represented 254 unique proteins, we investigated 458 of the 621 protein-cancer associations that were identified after multiple testing in the main analyses. Three *cis-p*QTL coding for higher T associations that were identified after multiple testing in the main analyses. Three cis-pQTL coding for higher TNFRSF14 were associated with a lower risk of NHL after correction for multiple testing (p < 0.05/939 tests b on cis-pQTL variants), 1:2559766:C:T [0.85 (0.79-0.91]]; 1:2559503:C:A, [0.85 (0.79-0.91)] and 1:2556714:A:G [0.86 (0.80-0.92)] (Figure 4). We found evidence to support the potential role of an additional 81 proteins in c (0.80-0.92)] (Figure 4). We found evidence to support the potential role of an additional 81 proteins in cancer risk
as indicated by 106 protein-cancer associations at $p<0.05$ which did not meet correction for multiple t as indicated by 106 protein-cancer associations at $p<0.05$ which did not meet correction for multiple testing

Circulating proteins with both prospective and exome-score associations

(Extended Table 6).
Circulating proteins with both prospective and exome-score associations
We derived exGS that combined known *cis* and *trans*-pQTLs to predict circulating protein-concentrations and
assessed their asso Circulating proteins

We derived exGS t

assessed their asses

associations across

28 associations inc we derived exds that combined known cis and trans-pQTLS to predict circulating protein concentrations and
assessed their associations with cancer risk. We were able to investigate 533 of the 621 protein-cancer
associations associations across 324 unique proteins. After correcting for multiple testing (0.05/533 exGS tests), we identified
28 associations, including 24 for NHL, 2 for leukemia (SRP14, TREML2), 1 for both liver (KRT18) and lung (28 associations, including 24 for NHL, 2 for leukemia (SRP14, TREML2), 1 for both liver (KRT18) and lung (TNR) (Figure 4). The strongest association was for SRP14 with leukemia [1.22 (1.16-1.28)] followed by KRT18 for liver $[1.29 (1.18-1.42)]$, CD1C for NHL $[1.11 (1.06-1.16)]$ and TNR for lung $[0.92 (0.89-0.95)]$. Additionally, we found 115 conventionally significant protein-cancer associations, representing 96 unique proteins (Extended Table 7) of
which 74 were directionally concordant with the results from the prospective analyses.
Integrated evidence of pr

Integrated evidence of protein-cancer associations

which 74 were directionally concordant with the results from the prospective analyses.

Integrated evidence of protein-cancer associations

We identified four proteins that were both associated with risk of cancer in main Integrated evidence of protein-cancer associations
We identified four proteins that were both associated with risk of cancer in main ana
concordant, conventionally significant support from all three additional analyses, i
 concordant, conventionally significant support from all three additional analyses, i.e. long (>7 year) time-to-
diagnosis, *cis*-pQTL, and exGS analyses: SFTPA2 for lung [1.24 (1.14-1.35)], TNFRSF1B [1.28 (1.19-1.37)] and diagnosis, cis-pQTL, and exas analyses: SFTPA2 for lung [1.24 (1.14-1.35)], TWEST 1D [1.28 (1.15-1.37)] and CD74
[1.68 (1.49-1.90)] for NHL and ADAM8 for leukemia [1.87 (1.69-2.06)] (Figure 5). Additionally, we found gene and observational evidence supporting the role of 45 unique proteins in the risk of cancer which were associated with cancers of blood (22 proteins), liver (11), lung (6), kidney (5), colorectum (3), prostate (1) (Table 2). with cancers of blood (22 proteins), liver (11), lung (6), lung (6), colorectum (3), prosecutely (1), colorectum
(1), prosecutely and all proteins), and all proteins (1), and all proteins (1), processes (1), provided (1),

Discussion
In this large prospective study of 1,463 proteins with the risk of up to 19 cancers, we identified 371 plasma protein markers of cancer risk, including 100 that were associated with cancer diagnosed more than seven years after
blood draw and many that also had support from complementary genetic analyses, which may suggest a role in
etiolo markers of cancer risk, including 100 that were extended more precise analyses, which may suggest a role in
etiology. Furthermore, 182 proteins were strongly associated with diagnosis within three years, suggesting
potenti

etiology. Furthermore, 182 proteins were strongly associated with diagnosis within three years, suggesting
potential relevance as biomarkers for early detection.
We identified both proteins that mark common processes acros We identified both proteins that mark common processes across cancer sites and those with associations specific
to a particular cancer. The proteins associated with risk of multiple cancers included GDF15, a stress-regulat Pote identified both proteins that mark common proce
to a particular cancer. The proteins associated with
hormone that we found to be associated with an
gastrointestinal tract, and hematological malignancies
was associated The proteins associated with risk of multiple cancers included GDF15, a stress-regulated
hormone that we found to be associated with an increased risk of eight cancers (liver, aerodigestive and
gastrointestinal tract, and The principle in the present of the proteins associated with an increased risk of eight cancers (liver, aerodigestive and gastrointestinal tract, and hematological malignancies), and MMP12, an enzyme expressed on macrophag matriointestinal tract, and hematological malignancies), and MMP12, an enzyme expressed on macrophages that
was associated with an increased risk of cancers of the stomach, colon, lung, and NHL.³¹ However, the majority o gastronous was associated with an increased risk of cancers of the stomach, colon, lung, and NHL.³¹ However, the majority of protein-cancer associations were cancer-site specific (225 of the 371 proteins), and many also protein-cancer associations were cancer-site specific (225 of the 371 proteins), and many also had majority mRNA expression on the cell or tissue of cancer origin. We note, however, that further evidence for proteins and r

protein-cancer associations were not protein-site specific the 371 proteins), and many also had majority many
expression on the cell or tissue of cancer origin. We note, however, that further evidence for proteins and risk expression on the cell or tissue of the cell or tissue of the cell or tissue of cell or tissue of the cell or
the cell or tissue of the cell or tissue of the cell origin. We found that protein-cancer associations were most less common cancer and cancer associations were most prevalent for cancers related to the blood or in tissues with
a role in the maintenance of blood composition or with a high throughput of blood, such as the liver, kidne a role in the maintenance of blood composition or with a high throughput of blood, such as the liver, kidneys, and
lungs. Further, the smaller number of protein associations for cancers with higher incidence in this study lungs. Further, the smaller number of protein associations for cancers with higher incidence in this study but
whose organs are not directly involved in blood composition (such as breast and prostate) may indicate a more
l whose organs are not directly involved in blood composition (such as breast and prostate) may indicate a more
localized effect and highlight the limitation of only measuring blood protein levels when investigating diseases localized effect and highlight the limitation of only measuring blood protein levels when investigating diseases in
other tissues. When, in the future, stage and histological grading information becomes available for cance other tissues. When, in the future, stage and histological grading information becomes available for cancers within
the UK Biobank or other cohorts, it may be possible to identify proteins associated with disease that has
 the UK Biobank or other cohorts, it may be possible to identify proteins associated with disease that has
progressed beyond the primary organ that may lead to more easily measurable effects in the circulation.
Integrating

Integrating prospective observational and genetic evidence for candidate etiological proteins

the UK Biobana or other considers the UK Biobana or other complements.

Integrating prospective observational and genetic evidence for candidate etiological proteins

We found four proteins that associated with cancer that progressed beyond the primary organ that may lead to more easily integrating prospective observational and genetic evidence for candidate etiological proteins
We found four proteins that associated with cancer that in obse we found four proteins that associated with earlier that in observational long time-to-diagnosis analyses, and cis-
pQTL and exGS analyses; CD74 and TNFRSF1B were associated with NHL, and ADAM8 and SFTPA2, were associated
 position is a final and lung cancer, respectively. While each of these three complementary analyses have their
own specific biases, the combination of concordant support from all methods may lead to greater confidence for
 with specific biases, the combination of concordant support from all methods may lead to greater confidence for a
role in cancer development.¹⁰ Each of these four also appear to have notable biological plausibility. CD74 role in cancer development.¹⁰ Each of these four also appear to have notable biological plausibility. CD74,
TNFRSF1B, and ADAM8 all have important roles in the immune system and have enrichment for mRNA expression
on can TNFRSF1B, and ADAM8 all have important roles in the immune system and have enrichment for mRNA expression
on candidate cells of origin for NHL and leukemia. Similarly, SFTPA2 has a well-described role in maintaining
healt on candidate cells of origin for NHL and leukemia. Similarly, SFTPA2 has a well-described role in maintaining
healthy lung function and is also majority expressed in alveolar cells, which are a candidate cell of origin for

healthy lung function and is also majority expressed in alveolar cells, which are a candidate cell of origin for
multiple common subtypes of lung cancer.³²
SRP14 was associated with the risk of leukemia in both observati multiple common subtypes of lung cancer.³²
SRP14 was associated with the risk of leukemia in both observational and exGS analyses and was more strongly
associated with risk of leukemia in people diagnosed within the firs associated with risk of leukemia in people diagnosed within the first three years. SRP14 has a well-described role in
protein targeting in the endoplasmic reticulum, has a high pLi, and is essential for leukemia and lymph protein targeting in the endoplasmic reticulum, has a high pLi, and is essential for leukemia and lymphoid
malignancy cell survival, as shown using CRISPR knockout models.³³ Notably, the SRP14 exGS association was
explai protein targeting in the endoption in the endoption and gradient models.³³ Notably, the SRP14 exGS association was explained by a single *trans* missense variant (9:5073770:G:T) in JAK2, that leads to constitutively acti explained by a single trans missense variant (9:5073770:G:T) in JAK2, that leads to constitutively active JAK2, which
is known to predispose to various forms of leukemia.³⁴⁻³⁶ Given *cis*-pQTL did not support a role for

is know to predisponent of imminent leukemia diagnosis, may indicate
constitutively active JAK2.
Similarly, higher FLT3LG was associated with a lower risk of prostate cancer in both observational and exGS
analyses. We foun Leukemia risk, it is therefore possible that states in any set with matter of imminent leukemia angles is constitutively active JAK2.

Similarly, higher FLT3LG was associated with a lower risk of prostate cancer in both ob Similarly, higher FLT3LG
Similarly, higher FLT3LG
analyses. We found that t
genes involved in the
[11:108267276:T:C], and T
increase risk of prostate analyses. We found that the FLT3LG exGS was largely explained by *trans-*pQTL that lie in established cancer risk genes involved in the regulation of cell division and DNA repair (CHEK2 [22:28695868:AG:A], ATM [11:1082672 analyses. We found that the FLT3LG exc3 was largely explained by trans-pQTL that lie in established cancer fisk
genes involved in the regulation of cell division and DNA repair (CHEK2 [22:28695868:AG:A], ATM
[11:108267276 [11:108267276:T:C], and TERT [5:1293971:C:T]). For example, carriers of the CHEK2 allele previously reported to increase risk of prostate cancer had lower circulating concentrations of FLT3LG.^{37,38} FLT3LG is predominant increase risk of prostate cancer had lower circulating concentrations of FLT3LG.^{37,38} FLT3LG is predominantly increase risk of prostate cancer had lower circulating concentrations of FLT3LG.^{37,38} FLT3LG is predominantly

increase risk of prostate cancer had lower circulating concentrations of FLT3LG.^{37,38} FLT3LG is predominant

expressed on dendritic cells to enhance tumor antigen presentation to facilitate anti-tumor immune responses.³⁹
Prostate cancer cases carrying high-risk genetic variants in DNA repair pathway genes, such as CHEK2, have a Processes carrying high-risk general mutation rates in the absence of effective tumor antigen presentation/immune surveillance would form a coherent biological explanation for higher cancer risk and shorter progression tim coherent biological explanation for higher cancer risk and shorter progression times. Therefore, lower FLT3LG may
serve as a potential biomarker of early cancer processes leading to diagnosis among carriers of established

contribution for the explanation for the processes leading to diagnosis among carriers of established
prostate cancer risk variants.
Together these findings highlight the need for research into the potential role of blood prostate cancer risk variants.

Together these findings highlight the need for research into the potential role of blood proteins as circulating

readouts that could indicate emerging early carcinogenic processes prior to Progether these findings high
readouts that could indicate
existing strategies that use ge
We also identified protein-ca
of effect Hsing cis-nOTL we

Together these theory of regalign the need of research into the potential respective to discussion readouts that could indicate emerging early carcinogenic processes prior to diagnosis, and that may complement existing str Existing strategies that use germline genetics to identify and monitor *at-risk* populations.
We also identified protein-cancer associations with support from genetic analyses but with a discordant direction
of effect. Us Existing strategies that use germline genetics to identify and monitor at-risk populations.
We also identified protein-cancer associations with support from genetic analyses but w
of effect. Using *cis*-pQTL, we identified of effect. Using *cis*-pQTL, we identified an inverse association of TNFRSF14, a gene with high pLi, with NHL risk,
while observational results suggested an association with higher risk, particularly within the initial thr of effect. Using as pQTL, we factured an inverse association of TNFRST-1, a gene with high pLi, with NHL risk,
while observational results suggested an association with higher risk, particularly within the initial three-ye multimetry that it has a protective role during NHL development.³⁰ TNFRSF14 may therefore be overexpressed as an anti-tumor response to the presence of disease, which could explain our findings. However, current protein follow-up. That it has a protective role during NHL development.³⁰ TNFRSF14 may therefore be overexpressed as an anti-tumor response to the presence of disease, which could explain our findings. However, current protein anti-tumor response to the presence of disease, which could explain our findings. However, current protein assay
technology limitations do not enable us to distinguish between multiple proteoforms that may contain higher
l technology limitations do not enable us to distinguish between multiple proteoforms that may contain higher
levels of TNFRSF14 with loss of function variants in these samples.
Previous studies of proteins and cancer risk

Previous studies of proteins and cancer risk

the levels of TNFRSF14 with loss of function variants in these samples.
 Previous studies of proteins and cancer risk

While there have been multiple previous case-control and cross-sectional studies of circulating prote Previous studies of proteins and cancer risk
While there have been multiple previous case-control and cross-se
risk (with blood taken at or after cancer diagnosis), there are lin
some previously reported prospective associ risk (with blood taken at or after cancer diagnosis), there are limited published prospective data. We replicate
some previously reported prospective associations for proteins and risk of cancer, which may serve as reassur ran previously reported prospective associations for proteins and risk of cancer, which may serve as reassuring
confirmation for the reproducibility of findings in this fast-emerging field of multiplex proteomics. We also
 som previously reported prospective findings in this fast-emerging field of multiplex proteomics. We also
identified many novel findings that may be due to the prospective study design and/or the large sample size. For
exa identified many novel findings that may be due to the prospective study design and/or the large sample size. For
example, we replicated the association of CDCP1 with lung cancer risk reported within the EPIC cohort, and al Example, we replicated the association of CDCP1 with lung cancer risk reported within the EPIC cohort, and also
found concordant evidence for risk proteins, such as CEACAM5, identified within up to three years prior to
dia Found concordant evidence for risk proteins, such as CEACAM5, identified within up to three years prior to diagnosis in the INTEGRAL project.^{19,37,38} We additionally identified risk associations with lung cancer for mul diagnosis in the INTEGRAL project.^{19,37,38} We additionally identified risk associations with lung cancer for multiple
proteins that were either not previously investigated or that did not meet the significance criteria presting within previous studies. For colorectal cancer, we were not able to replicate the previously reported
associations for several proteins identified in prospective studies using samples taken up to three years prio associations for several proteins identified in prospective studies using samples taken up to three years prior to diagnosis or in those studies with relatively modest numbers of incident cases ($n \le 100$).^{42,43} We also diagnosis or in those studies with relatively modest numbers of incident cases ($n \le 100$).^{42,43} We also did not replicate protein risk associations previously reported for pancreatic cancer.⁴⁴ Nonetheless, our findin diagnosis or in those studies with relatively modest numbers of incident cases (n ≤ 100).^{42,43} We also did not replicate protein risk associations previously reported for pancreatic cancer. ⁴⁴ Nonetheless, our fin replicate protein risk associations previously reported for pancreatic cancer.⁴⁴ Nonetheless, our findings are in-line
with some of those reported in a cross-cancer case-control study (with bloods collected at or after d

within the Uppsala-Umeå Comprehensive Cancer Consortium biobank; we replicated the reported association of
GFAP with glioma and the associations of CNTN5, SLAMF7, MZB1, QPCT and TNFRSF13B with multiple myeloma. ⁴⁵
Our st GFAP with glioma and the associations of CNTN5, SLAMF7, MZB1, QPCT and TNFRSF13B with multiple myeloma.⁴⁵
Our study has several notable strengths. We examined the role of over one thousand blood proteins in cancer
develo Our study has several notable strengths. We examined the role of over one thousand blood proteins in cancer development and report several hundred novel protein and cancer associations. The detailed information in the UK B development and report several hundred novel protein and cancer associations. The detailed information in the The plus and report and report of control characteristics (including cohort-wide exome data) has made it possible to
dssess the potential for cancer-specific confounders to influence our findings and to run complementary g The same of the potential for cancer-specific confounders to influence our findings and to run complementary genetic
analyses on the majority of candidate proteins identified in our observational analyses. Further, informa analyses on the majority of candidate proteins identified in our observational analyses. Further, information on cancer diagnosis was obtained from data linkage, thus minimizing selective dropouts. The cross-cancer approac cancer diagnosis was obtained from data linkage, thus minimizing selective dropouts. The cross-cancer approach
also reduced outcome selection bias and enabled us to find proteins associated with both multiple and specific
 also reduced outcome selection bias and enabled us to find proteins associated with both multiple and specific
cancers, and their subtypes. also reduced outcome selection bias and the find proteins associated with both multiple and specific
cancers, and their subtypes. cancers, and their subtypes.

associations were being driven by altered protein levels in individuals who were likely to have preclinical disease at
blood draw and/or persisted with longer follow-up. Nonetheless, some hematological cancers can be prese blood draw and/or persisted with longer follow-up. Nonetheless, some hematological cancers can be present long
before clinical diagnosis, such as chronic lymphocytic leukemia.^{46,47} Further, liver and kidney disease both before clinical diagnosis, such as chronic lymphocytic leukemia.^{46,47} Further, liver and kidney disease both have risk factors, including cirrhosis and chronic kidney disease, respectively, that we may expect to perturb factors, including cirrhosis and chronic kidney disease, respectively, that we may expect to perturb the blood
proteome far in advance of diagnosis. It is therefore possible that associations with risk observed more than s proteome far in advance of diagnosis. It is therefore possible that associations with risk observed more than seven
years prior to diagnosis may still be due to either reverse causality or be markers of established risk fa proteins and not example and state of established risk factors and not etiological. However, proteins associated with cancer risk long before diagnosis and that have support from complementary genetic analyses may warrant

expectively and that have support from

to diagnosis and that have support from

complementary genetic analyses may warrant follow-up as potential cancer risk factors.

We also note that we only analyzed protein concentrat ethial. The complementary genetic analyses may warrant follow-up as potential cancer risk factors.
We also note that we only analyzed protein concentrations measured at baseline and therefore were not able to
address poten We also note that we only analyzed protein concentrations measured at baseline and t
address potential regression dilution bias, which may have led to underestimates of relatively
is the largest cohort study of plasma prot address potential regression dilution bias, which may have led to underestimates of relative risks. Also, while this
is the largest cohort study of plasma proteins and cancer to date, we had relatively limited power to det and the largest cohort study of plasma proteins and cancer to date, we had relatively limited power to detect
protein-cancer associations for less common cancer sites and subsites that nonetheless hold substantial public
h is the largest consistent process common cancer sites and subsites that nonetheless hold substantial public
health importance. Finally, the UK Biobank predominantly consists of adults of White ethnicity and who have a
more provided in importance. Finally, the UK Biobank predominantly consists of adults of White ethnicity and who have a more favorable risk profile compared to the national UK population.¹⁵ Proteomics holds significant promis more favorable risk profile compared to the national UK population.¹⁵ Proteomics holds significant promise for
developing future cancer prevention initiatives that are needed to address the predicted increase in cancer b more favorable risk profile compared to the national UK population.²⁵ Proteomics holds significant promise for developing future cancer prevention initiatives that are needed to address the predicted increase in cancer b

among diverse populations, and so further studies into the proteomics of cancer risk in non-White populations are
necessary.⁴⁸
There are several research priorities leading from our findings that are necessary to pursue among any.⁴⁸
There are several research priorities leading from our findings that are necessary to pursue to more fully
understand the roles of proteins in cancer development and progression. Priorities are more large-sc understand the roles of proteins in cancer development and progression. Priorities are more large-scale
prospective data from mature cohorts to replicate our findings and further complementary genetic studies,
including Me prospective data from mature cohorts to replicate our findings and further complementary genetic studies, including Mendelian randomization analyses. As new GWAS data for cancers of the blood, liver, and kidney become avai prospective data for cancers of the blood, liver, and kidney
including Mendelian randomization analyses. As new GWAS data for cancers of the blood, liver, and kidney
become available, further investigations into etiology u including including Mendelian randomization into etiology using genetic epidemiology will be possible. Where protein
associations prove replicable, it will be necessary to better understand their role at the tissue and cel associations prove replicable, it will be necessary to better understand their role at the tissue and cellular level.
This is of particular interest given proteins are the target of 98% of all drugs and that 38 of our cand This is of particular interest given proteins are the target of 98% of all drugs and that 38 of our candidate etiological proteins are the target of existing drugs, of which nine had further directionally concordant eviden etiological proteins are the target of existing drugs, of which nine had further directionally concordant evidence
from genetic analyses supporting their role in cancer development.⁴⁹ Nonetheless, substantial additional from genetic analyses supporting their role in cancer development.⁴⁹ Nonetheless, substantial additional research

from genetic analyses supporting their role in cancer development .³⁹ Nonetheless, substantial additional research
would be needed to assess any potential for therapeutic prevention, including functional and experimental Would be to assess potential toxicity.
In conclusion, we discovered multiple associations between blood proteins and cancer risk. Many of these were
detectable more than seven years before cancer diagnosis and had concorda and these to asset performant toning.
In conclusion, we discovered multiple
detectable more than seven years be
suggesting they may have a role in ca
processes among carriers of establish
stratification and early diagnosis detectable more than seven years before cancer diagnosis and had concordant evidence from genetic analyses, suggesting they may have a role in cancer development. We also identified proteins that may mark early cancer proc suggesting they may have a role in cancer development. We also identified proteins that may mark early cancer
processes among carriers of established cancer risk variants, which may serve as potential biomarkers for risk
s processes among carriers of established cancer risk variants, which may serve as potential biomarkers for risk
stratification and early diagnosis. processes among carriers of early diagnosis.
The cancer risk variants, which may see the cancer risk v stratification and early diagnosis.

List of tables and figures

Main

Table 2. Baseline characteristics of the OK Biobank analysis cohort, overall, by sex, and in those who developed any
malignant cancer
Table 2. Summary of protein-cancer associations that have support from one or more of lo manghant cancer
Table 2. Summary
7 years), cis-pQTL
Figure 1 – Volcano
Six volcano plots c

Table 2. Summary of protein-cancer associations that have support from one or more or long time-to-diagnosis (>
Tigure 1 – Volcano plots for the prospective association of circulating proteins with risk of cancer
Six volca 7 years), cis-pQTL, or exome protein score analyses
Figure 1 – Volcano plots for the prospective associat
Six volcano plots displaying the results from the pro
risk grouped, where possible, by organ systems: a) f
and brain Figure 1 – Volcano plots for the prospective association of chediating procents with risk of cancer
Six volcano plots displaying the results from the prospective observational analyses of 1,463 prote
risk grouped, where po risk grouped, where possible, by organ systems: a) hematological cancers, b) liver cancer, c) cancers of the lung
and brain, d) renal, prostate, and bladder cancers, e) breast, ovarian, and endometrial cancers, and f) can and brain, d) renal, prostate, and bladder cancers, e) breast, ovarian, and endometrial cancers, and f) cancers of
the stomach, colorectum and esophagus. Hazard ratios per SD for cancer risk is plotted on the x-axis while the stomach, colorectum and esophagus. Hazard ratios per SD for cancer risk is plotted on the x-axis while $-log_{10}$ p-
values are plotted on the y-axis. Protein names and hazard ratios are labelled to highlight a selectio values are plotted on the y-axis. Protein names and hazard ratios are labelled to highlight a selection of
associations significant after correction for multiple testing $(p < 0.05/639)$.
Figure 2 – Evidence for cellular an

associations significant after correction for multiple testing ($p < 0.05/639$).
 Figure 2 – Evidence for cellular and tissue enrichment of mRNA expression for cancer risk proteins

This set of figures displays the enric Figure 2 – Evidence for cellular and tissue enrichment of mRNA expression
This set of figures displays the enrichment of mRNA expression at the cellu
proteins: a) summarizes the count of proteins that associate with cancer Figure 2 – Evidence for cendiar and tissue enrichment of mRNA expression for cancer risk procents.
This set of figures displays the enrichment of mRNA expression at the cellular and tissue level for caproteins: a) summariz This set of interesting and many present that associate with cancer risk and whose genes are either enrifor expression (between 10% and 50% of total expression) or majority expressed (greater than 50% of total expression) proteins: a) on the candidate cell or tissue of cancer origin by cancer site; b) displays the cross-tissue mRNA
expression) on the candidate cell or tissue of cancer origin by cancer site; b) displays the cross-tissue mRNA expression) on the candidate cell or tissue of cancer origin by cancer site; b) displays the cross-tissue mRNA
expression of the genes that code for proteins associated with cancer risk that are also majority expressed in
 expression of the genes that code for proteins associated with cancer risk that are also majority expressed in
tissue; c) displays the cross-cellular mRNA expression of the genes that code for proteins associated with can
 expression of the genes that code for proteins associated with cancer
tissue; c) displays the cross-cellular mRNA expression of the genes that code for proteins associated with cancer
risk that are also majority expressed

risk that are also majority expressed in one cell. Both b) tissues and b) cells are grouped by higher-order organ
systems.
Figure 3 – Volcano plots for the prospective association of circulating proteins with risk of can

Two volcano plots display the results from prospective observational analyses of 1,463 proteins with cancer risk s
Fi**gure 3 -**
diagnosis
Two volca
stratified
draw (lef Figure 3 – Volcano plots for the prospective association of circulating proteins with risk of cancer by time to
diagnosis
Two volcano plots display the results from prospective observational analyses of 1,463 proteins with **Two volca**
stratified
draw (left
axis while
selection Tratified by time from blood draw to diagnosis, with analyses among cases diagnosed within three years of blood
draw (left) and after seven years of blood draw (right). Hazards ratios for cancer risk per SD are plotted on draw (left) and after seven years of blood draw (right). Hazards ratios for cancer risk per SD are plotted on the x-
axis while $-\log_{10} p$ -values are plotted on the y-axis. Protein names and hazard ratios are labelled to h

axis while value of associations significant after correction for multiple testing (p < 0.05/639).

Figure 4 – Mirror Manhattan plot for the association of genetically predicted protein concentrations and cance

risk using

This mirror Manhattan plot displays the results of each *cis-*pQTL (top) in the full exome-sequencing cohort within Figure 4 – Mirror Manhattan plot for the association of genetically predicted protein corrections and exame scores
This mirror Manhattan plot displays the results of each *cis*-pQTL (top) in the full exome-
the UK Biobank Fisk using *cis*-pQTL and exome scores
Fisk using *cis*-pQTL and exome scores
This mirror Manhattan plot displays the results of each *cis*-pQTL (top) in the full exome-sequencing cohort within
the UK Biobank across Europe risk using cis-pQTL and exome scores
This mirror Manhattan plot displays t
the UK Biobank across European sam
results on cancer risk. The y-axis repre
score results for genetically predicted
conventional p < 0.05 significa This mirror Manhattan plot displays the results of each cis-pQTL (top) in the full exome-sequencing conot within
the UK Biobank across European samples for proteins passing correction for multiple testing in the observatio results on cancer risk. The y-axis represents the - log_{10} p-values. The bottom of this plot contains the exome-wide
score results for genetically predicted proteins. Markers colored in grey represent analyses that did no score results for genetically predicted proteins. Markers colored in grey represent analyses that did not reach the
conventional p < 0.05 significance threshold, while markers in blue represent conventionally significant a conventional $p < 0.05$ significance threshold, while markers in blue represent conventionally significant analyses. I
a *cis*-variant or an exome-wide score passed Bonferroni significance, those markers are colored by the a *cis*-variant or an exome-wide score passed Bonferroni significance, those markers are colored by the cancer site
of association. Purple markers represent non-Hodgkin lymphoma (NHL), light brown represents leukemia, gree a cis-variant or an exome-wide score passed Bonferroni significance, those markers are colored by the cancer site
of association. Purple markers represent non-Hodgkin lymphoma (NHL), light brown represents leukemia, green
 for liver cancer and pink for lung cancer. Red dash lines represent the threshold for Bonferroni multiple test
the threshold for Bonferroni multiple test
of the threshold for Bonferroni multiple test
of the threshold for B for liver cancer and pink for lung cancer. Red dash lines represent the threshold for Bonferroni multiple test

comparison, the relative risk per standard deviation increase. Cis-variants were adjusted to be on the same scale.

Figure 5. – Forrest plots for the prospective and genetic associations of SFPTA2 with lung cancer risk, CD

the relative risk per standard deviation increase. Cis-variants were adjusted to be on the same scale.
Figure 5. – Forrest plots for the prospective and genetic associations of SFPTA2 with lung cancer risk,
TNFRSF1B with r FIGURE 5. FORES POLS FOR THE PROSPECTIVE AND BETTAL MISSON OF STETAZ WITHING CAREFTANT CDTTANT AND THE TISTS FOR THE PROTECT TISTS FOR THE PROTECT IS AN Forrest plots display the association of each of CD74 and TNFRSF1B with risk of no
ADAM8 and SFTPA2, with risk of leukemia and lung cancer, respectively. For each
evidence for the association of concentrations with cancer For each protein-gram stream and lung cancer, respectively. For each protein-cancer association
ADAM8 and SFTPA2, with risk of leukemia and lung cancer, respectively. For each protein-cancer association
evidence for the as ADAMBED AND AND ADDITED AND THE RESEARCH CONTROLLING AND THE VEHICLE INTERNATION EVIDENCY. THE VEHICLE IN ANDE
ADAMS and SET SO, as well as models stratified by time-to-diagnosis, and from exome proteins score and *cis-*pQ evidence for the association of concentration of concentrations with cancer risk is presented from exame proteins score and *cis-pQTL* analyses.

analyses. models per SD, as well as models stratified by time-to-diagnosis, and from exome proteins score and cis-pQTL
analyses.

analyses. Extended Methods and Figures

Extended figure 1 – Study design flow chart and results summary
Extended figure 2 – Percentage change in the log hazard ratios between fully and minimally adjusted models

 Extended Tables

Extended figure 2 – Percentage change in the log hazard ratios between rany and minimally adjusted models
Extended Table 1 - Number of cases and age of diagnosis by cancer sub-site in all participants, and in men and wom
E Extended Table 1 - Number of cases and age of diagnosis by cancer sub-site in all participants, and in men and women

Extended Table 2 - UK Biobank exome sequencing cohort numbers per cancer site

Extended Table 3 - All protein-cancer associations from minimally adjusted, multivariable-adjusted and by time-todiagnosis analyses

Extended Table 4 - Protein-cancer associations that pass multiple testing correction stratified by sex

Extended Table 5 - Protein-cancer associations that pass multiple test correction mapped to currently available drugs

Extended Table 6 - Cis and trans single variant affecting protein-cancer associated proteins on cancer risk and exome score weights

Extended Table 7 - Association of exome score predicted protein concentration with cancer risk for protein-cancer associations that passed multiple testing correction

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . medRxiv preprint doi: [https://doi.org/10.1101/2023.07.28.23293330;](https://doi.org/10.1101/2023.07.28.23293330) this version posted August 5, 2023. The copyright holder for this preprint
(**which was not certified by peer review)** is the author/funder, who has granted

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . medRxiv preprint doi: [https://doi.org/10.1101/2023.07.28.23293330;](https://doi.org/10.1101/2023.07.28.23293330) this version posted August 5, 2023. The copyright holder for this preprint
(**which was not certified by peer review)** is the author/funder, who has granted

Values are presented as mean (standard deviation) unless otherwise specified.

Table 2. Summary of protein-cancer associations* that have support from one or more of long lagtime, *cis-*pQTL, or exome protein score analyses

The copyright holder for this preprint this version posted August 5, 2023. [;](https://doi.org/10.1101/2023.07.28.23293330) <https://doi.org/10.1101/2023.07.28.23293330> doi: medRxiv preprint

*protein-cancer associations in the prospective cohort analyses that were significant after corrections for the effective number of tests.

**n/N represents the number of protein-cancer associations that have support from one or more of long lagtime, cis-pQTL, or exome protein score analyses/ the total protein-cancer site associations

For protein-cancer associations with >1 association with a cancer and i's subsites we only present the one with the highest tier

Bold proteins represent proteins-cancer associations that are specific to one cancer site after corrections for the effective number of tests.

Proteins that are underlined are targets of approved drugs with ^I indicating the action of its approved drug increases the risk of the corresponding cancer and ^D indicating the action of its approved drug decreases the risk of the corresponding cancer ^B indicating the presence of approved drugs with both an increased and

decreased risk.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . medRxiv preprint doi: [https://doi.org/10.1101/2023.07.28.23293330;](https://doi.org/10.1101/2023.07.28.23293330) this version posted August 5, 2023. The copyright holder for this preprint
(**which was not certified by peer review)** is the author/funder, who has granted

- References
1. Knuppel, A. *et al.* Circulating Insulin-like Growth Factor-I Concentrations and Risk of 30 Cancers: Prospective Analyses in UK Biobank. Cancer Res. 80, 4014-4021 (2020).
- 2. Watts, E. L. et al. Circulating insulin-like growth factors and risks of overall, aggressive and earlyonset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis. Int. J. Epidemiol. 52, 71-86 (2023).
- Smith Byrne, K. et al. The role of plasma microseminoprotein-beta in prostate cancer: an 3. Smith Byrne, K. *et al.* The role of plasma microseminoprotein-beta in prostate cancer: an
observational nested case-control and Mendelian randomization study in the European prospective investigation into cancer and nutrition. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 30, 983-989 (2019).
- Menon, U. et al. Ovarian cancer population screening and mortality after long-term follow-up in the 4. Menon, U. *et al.* Ovarian cancer population screening and mortality after long-term follow-up in t
UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. The
Lancet 397, 2182–2193 (2021). Lancet 397, 2182–2193 (2021).
5. Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium for Early Detection of
- Lung Cancer. Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins. JAMA Oncol. 4, e182078 (2018).
- Ballehaninna, U. K. & Chamberlain, R. S. The clinical utility of serum CA 19-9 in the diagnosis, 6. prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J. prognosis and management or pancreatic adenocarcinoma: An evidence based appraisal. J.
Gastrointest. Oncol. 3, 105–119 (2012). Gastrointest. Oncol. 3, 105–119 (2012).
7. Lane, J. A. et al. Latest results from the UK trials evaluating prostate cancer screening and
- treatment: the CAP and ProtecT studies. Eur. J. Cancer Oxf. Engl. 1990 46, 3095-3101 (2010).
- Johansson, \AA . et al. Identification of genetic variants influencing the human plasma proteome. Proc. 8. Johansson, Å. *et al.* Identification of genetic variants influencients influencients influencients influencien
1**10**, 4673–4678 (2013).
- 9. Suhre, K., McCarthy, M. I. & Schwenk, J. M. Genetics meets proteomics: perspectives for large population-based studies. Nat. Rev. Genet. 22, 19-37 (2021). population-based studies. Nat. Rev. Genet. 22, 19–37 (2021).

- 10. Munafò, M. R. & Davey Smith, G. Robust research needs many lines of evidence. Nature 553, 399– 401 (2018).
11. DeBoever, C. *et al.* Medical relevance of protein-truncating variants across 337,205 individuals in
- the UK Biobank study. Nat. Commun. 9, 1612 (2018).
- 12. Gkatzionis, A., Burgess, S. & Newcombe, P. J. Statistical methods for cis-Mendelian randomization with two-sample summary-level data. Genet. Epidemiol. 47, 3-25 (2023).
- 13. Zhong, W. et al. Whole-genome sequence association analysis of blood proteins in a longitudinal 13. Zhong, W. et al. Whole-genome sequence association analysis of blood proteins in a longitudinal
wellness cohort. Genome Med. 12, 53 (2020). wellness cohort. *Genome Med.* 12, 53 (2020).
14. Lawlor, D. A., Tilling, K. & Davey Smith, G. Triangulation in aetiological epidemiology. *Int. J.*
- Epidemiol. dyw314 (2017) doi:10.1093/ije/dyw314.
- 15. Fry, A. et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. Am. J. Epidemiol. 186, 1026-1034 (2017).
- 16. Collins, R. What makes UK Biobank special? The Lancet 379, 1173-1174 (2012).
- 17. Sun, B. B. et al. Genetic regulation of the human plasma proteome in 54,306 UK Biobank participants. 2022.06.17.496443 Preprint at https://doi.org/10.1101/2022.06.17.496443 (2022).
- 18. Wik, L. et al. Proximity Extension Assay in Combination with Next-Generation Sequencing for Highthroughput Proteome-wide Analysis. Mol. Cell. Proteomics MCP 20, 100168 (2021).
- 19. Albanes, D. et al. The blood proteome of imminent lung cancer diagnosis. Nat. Commun. 14, 3042 19. Albanes, D. et al. The blood proteome of imminent lung cancer diagnosis. Nat. Commun. 14, 3042 . (2023).
-20. Protocol for Processing UKB Whole Exome Sequencing Data Sets. https://dnanexus.gitbook.io/uk
-20. Protocol for Processing UKB Whole Exome Sequencing Data Sets. https://dnanexus.gitbook.io/uk
- biobank-rap/science-corner/whole-exome-sequencing-oqfe-protocol/protocol-for-processing-ukbwhole-exome-sequencing-data-sets.

- 21. Dhindsa, R. S. et al. Influences of rare protein-coding genetic variants on the human plasma
proteome in 50,829 UK Biobank participants. 2022.10.09.511476 Preprint at https://doi.org/10.1101/2022.10.09.511476 (2022).
- 22. Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff. Fly (Austin) 6, 80-92 (2012).
- 23. Thul, P. J. & Lindskog, C. The human protein atlas: A spatial map of the human proteome. Protein 23. Thul, P. J. & Lindskog, C. The human protein atlas: A spatial map of the human proteome. Protein
Sci. Publ. Protein Soc. 27, 233–244 (2018). Sci. Publ. Protein Soc. 27, 233–244 (2018).
24. Ochoa, D. et al. The next-generation Open Targets Platform: reimagined, redesigned, rebuilt.
- Nucleic Acids Res. 51, D1353-D1359 (2023).
- 25. Mendez, D. et al. ChEMBL: towards direct deposition of bioassay data. Nucleic Acids Res. 47, D930– 25. Mendez, D. et al. ChEMBL: towards direct deposition of bioassay data. Nucleic Acids Res. 47, D930– D940 (2019).
26. DailyMed. https://www.dailymed.nlm.nih.gov/dailymed/.
-
- 27. Electronic medicines compendium (emc). https://www.medicines.org.uk/emc#gref.
- 28. Chen, Z.-L. et al. A high-speed search engine pLink 2 with systematic evaluation for proteome-scale identification of cross-linked peptides. Nat. Commun. 10, 3404 (2019).
- 29. Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 29. Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456
humans. *Nature* 581, 434–443 (2020). humans. *Nature* 581, 434–443 (2020).
30. Martínez-Jiménez, F. *et al.* A compendium of mutational cancer driver genes. *Nat. Rev. Cancer* 20,
- 30. Martínez-Jiménez, F. et al. A compendium of mutational cancer driver genes. Nat. Rev. Cancer 20, 555–572 (2020).
31. Kim, K. H. & Lee, M.-S. GDF15 as a central mediator for integrated stress response and a promising
- therapeutic molecule for metabolic disorders and NASH. Biochim. Biophys. Acta BBA Gen. Subj. therapeutic molecule for metabolic disorders and NASH. Biochim. Biophys. Acta BBA - Gen. Subj. 1865, 129834 (2021).
32. Floros, J., Thorenoor, N., Tsotakos, N. & Phelps, D. S. Human Surfactant Protein SP-A1 and SP-A2
- Variants Differentially Affect the Alveolar Microenvironment, Surfactant Structure, Regulation and Variants Differentially Affect the Alveolar Microenvironment, Surfactant Structure, Regulation and

Function of the Alveolar Macrophage, and Animal and Human Survival United Survival United Survival United Survival U
Front. Immunol. 12, (2021). Front. Immunol. 12, (2021).
33. Tsherniak, A. *et al.* Defining a Cancer Dependency Map. *Cell* 170, 564-576.e16 (2017).

-
- 34. Beer, P. A. et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 115, 2891-2900 (2010).
- 35. Gnanasambandan, K., Magis, A. & Sayeski, P. P. The Constitutive Activation of Jak2-V617F is Mediated by a π Stacking Mechanism Involving Phe 595 and Phe 617. Biochemistry 49, 9972–9984 Mediated by a n Stacking Mechanism Involving Phe 595 and Phe 617. Biochemistry 49, 9972–9984
(2010). (2010).
36. Benton, C. B. *et al.* Janus kinase 2 variants associated with the transformation of myeloproliferative
- neoplasms into acute myeloid leukemia. Cancer 125, 1855–1866 (2019).
- 37. Dagnino, S. et al. Prospective Identification of Elevated Circulating CDCP1 in Patients Years before Onset of Lung Cancer. Cancer Res. 81, 3738-3748 (2021).
- 38. Robbins, H. A. et al. Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program. Ann. validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program. Ann.
Epidemiol. 77, 1–12 (2023). Epidemiol. 77, 1–12 (2023).
39. Wilson, K. R., Villadangos, J. A. & Mintern, J. D. Dendritic cell Flt3 – regulation, roles and
- repercussions for immunotherapy. Immunol. Cell Biol. 99, 962-971 (2021).
- 40. Herberts, C., Wyatt, A. W., Nguyen, P. L. & Cheng, H. H. Genetic and Genomic Testing for Prostate Cancer: Beyond DNA Repair. Am. Soc. Clin. Oncol. Educ. Book e390384 (2023) cancer: Beyond DNA Repair. A*m. Soc. Clin. Oncol. Educ. Book e390384 (2023)*
doi:10.1200/EDBK_390384. doi:10.1200/EDBK_390384.
41. Gerhauser, C. et al. Molecular evolution of early onset prostate cancer identifies molecular risk
- markers and clinical trajectories. Cancer Cell 34, 996-1011.e8 (2018).
- 42. Sun, X. et al. Prospective Proteomic Study Identifies Potential Circulating Protein Biomarkers for 42. Sun, X. et al. Prospective Proteomic Study Identifies Potential Circulating Protein Biomarkers for
Colorectal Cancer Risk. *Cancers* 14, 3261 (2022). Colorectal Cancer Risk. Cancers \mathbf{I} , 3261 (2022).
- 43. Harlid, S., Myte, R. & Van Guelpen, B. The Metabolic Syndrome, Inflammation, and Colorectal
Cancer Risk: An Evaluation of Large Panels of Plasma Protein Markers Using Repeated, Prediagnostic Samples. Mediators Inflamm. 2017, 4803156 (2017).
- 44. Kartsonaki, C. et al. Circulating proteins and risk of pancreatic cancer: a case-subcohort study among Chinese adults. Int. J. Epidemiol. 51, 817-829 (2022).
- 45. Álvez, M. B. et al. Next generation pan-cancer blood proteome profiling using proximity extension 45. Alvez, M. B. et al. Next generation pan-cancer blood proteome proming using proximity extension
assay. Nat. Commun. 14, 4308 (2023). assay. Nat. Commun. **14**, 4308 (2023).
46. Kolijn, P. M. et al. High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16
- years prior to diagnosis. Blood 139, 1557-1563 (2022).
- 47. Kaaks, R. et al. Lag times between lymphoproliferative disorder and clinical diagnosis of chronic lymphocytic leukemia: a prospective analysis using plasma soluble CD23. Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol. 24, 538-545 (2015).
- 48. Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA. Cancer J. Clin. 71, 209-249 (2021).
- 49. Langenberg, C., Hingorani, A. D. & Whitty, C. J. M. Biological and functional multimorbidity—from mechanisms to management. Nat. Med. 29, 1649-1657 (2023). mechanisms to management. Nat. Med. 29, 1649–1657 (2023).

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . medRxiv preprint doi: [https://doi.org/10.1101/2023.07.28.23293330;](https://doi.org/10.1101/2023.07.28.23293330) this version posted August 5, 2023. The copyright holder for this preprint
(**which was not certified by peer review)** is the author/funder, who has granted

Figure 1 – Volcano plots for the prospective association of circulating proteins with risk of cancer

÷

Figure 2 – Evidence for cellular and tissue enrichment of mRNA expression for cancer risk proteins

A.

Figure 3 – Volcano plots for the prospective association of circulating proteins with risk of cancer by time to diagnosis

Figure 4 – Mirror Manhattan plot for the association of genetically predicted protein concentrations and cancer risk using cis-pQTL and exome scores

Figure 5. – Forrest plots for the prospective and genetic associations of SFPTA2 with lung cancer risk, CD74 and TNFRSF1B with risk of non-Hodgkin lymphoma, and ADAM8 with risk of leukemia